Shots:

• The P-III (CheckMate -9ER) trial evaluates Opdivo + Cabometyx vs sunitinib in 651 patients with RCC. The trial is sponsored by BMS & Ono & co-funded by Exelixis, Ipsen & Takeda
• The results showed sustained efficacy benefits & response rate along with HRQoL improvements in a separate analysis with a median follow-up of 32.9mos., no new safety signals were observed, improvements in m-OS (37.7mos. vs 34.3mos.) with 30% reduction in risk of death, m-PFS (16.6mos. vs 8.3mos.)
• Additonally, ORR (55.7% vs 28.4%), m-DoR (23.1mos. vs 15.1mos.), CR rate (12.4% vs 5.2%), patients experienced TRAE (97.2% vs 93.1%) along with tumor shrinkage benefits, (65.0% vs 54.1%) had a grade ≥3 TRAE

 Ref: Exelixis | Image: BMS